MedTrace Logo

Artificial Intelligence to Improve Detection and Risk Stratification of Acute Pulmonary Embolism (AID-PE)

NCT06093217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3872

Last updated 2025-02-13

No results posted yet for this study

Summary

The goal of this exploratory observational study is to assess the feasibility and real-world clinical impact of implementing Artificial Intelligence (AI) software for the detection of acute Pulmonary Embolism (PE) in patients who undergo Computed Tomography Pulmonary Angiogram (CTPA). The main questions that this study aims to answer are:

\[Question 1\] What is the real-world impact of AI on the clinical outcomes and decision making by radiologists and clinicians in the management of acute PE?

\[Question 2\] Is AI software for the detection of acute PE acceptable to use in clinical practice and do they have a favourable impact on clinical workload?

\[Question 3\] Is it cost-effective to implement AI software for the detection of acute PE in clinical practice?

Patients having a CTPA for the detection of acute PE will have their imaging analysed by AI software in combination with a human radiologist. Researchers will aim to compare the clinical and radiology specific outcomes with a retrospective cohort of patients who have had standard routine radiology reporting.

Conditions

Interventions

DEVICE

Artificial Intelligence

AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist

Sponsors & Collaborators

  • University of Bath

    collaborator OTHER

  • University of Bristol

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • Royal United Hospitals Bath NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Jonathan Rodrigues, MBBS FRCR · Royal United Hospitals Bath NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2025-01-08
Completion
2025-02-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093217 on ClinicalTrials.gov